InflaRx (IFRX) Non Operating Income (2017 - 2024)
InflaRx (IFRX) posted Non Operating Income of -$3.1 million for Q1 2024, down 686.06% sequentially from $524857.7 in Q1 2023, and down 686.06% YoY from $524857.7 in Q2 2023.
InflaRx (IFRX) Non Operating Income (2017 - 2024) Analysis & Trends
InflaRx has reported Non Operating Income for 8 years, with the latest figure at -$3.1 million in Q1 2024.
- Quarterly Non Operating Income fell 686.06% year-over-year to -$3.1 million in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $3.2 million (down 41.7% YoY) and the FY2025 annual result came in at $2.0 million, down 40.64% from the prior year.
- Non Operating Income eased to -$3.1 million in Q1 2024 per IFRX's latest filing, from $524857.7 in the prior quarter.
- Over five years, Non Operating Income peaked at $3.7 million in Q4 2022 and troughed at -$3.1 million in Q1 2024.
- A 5-year average of $539937.0 and a median of $524857.7 in 2023 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2020 and 2024: Non Operating Income jumped 236.37% in 2020, then tumbled 686.06% in 2024.
- Over 5 years, Non Operating Income stood at $1.8 million in 2020, then grew by 12.41% to $2.0 million in 2021, then jumped by 84.41% to $3.7 million in 2022, then tumbled by 85.88% to $524857.7 in 2023, then slumped by 686.06% to -$3.1 million in 2024.
- According to Business Quant data, Non Operating Income over the past three periods registered -$3.1 million, $524857.7, and $3.7 million for Q1 2024, Q1 2023, and Q4 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -3.08 Mn |
| Mar 31, 2023 | 524,857.71 |
| Dec 31, 2022 | 3.72 Mn |
| Dec 31, 2021 | 2.02 Mn |
| Sep 30, 2021 | -799,145.23 |
| Dec 31, 2020 | 1.79 Mn |
| Sep 30, 2020 | -525,419.83 |
| Jun 30, 2020 | -493,997.16 |
| Mar 31, 2020 | 1.70 Mn |
| Dec 31, 2019 | 6.79 Mn |
| Sep 30, 2019 | 1.41 Mn |
| Jun 30, 2019 | -2.30 Mn |
| Mar 31, 2019 | -1.25 Mn |
| Dec 31, 2018 | -3.72 Mn |
| Sep 30, 2018 | 1.93 Mn |
| Jun 30, 2018 | 6.81 Mn |
| Mar 31, 2018 | -2.36 Mn |
| Dec 31, 2017 | 8.58 Mn |
| Sep 30, 2017 | -988,228.20 |
| Jun 30, 2017 | -925,820.53 |